一种抗新型冠状病毒的全人源单克隆抗体及其用途
本发明涉及一种抗新型冠状病毒的全人源单克隆抗体及其用途，属于生物工程技术领域。所述的全人源单克隆抗体具有重链可变区和轻链可变区；重链可变区的氨基酸序列如SEQ ID NO:15所示；轻链可变区的氨基酸序列如SEQ ID NO:16所示。本发明还提供该抗体的编码基因、表达载体、用途和组合物。本发明的结合分子能阻止新型冠状病毒侵染易感细胞，且是全人源的，与其它动物源性(如鼠源性)抗新型冠状病毒的分子相比，免疫原性低，且亲和性良好，不仅治疗效果好，而且副作用低，同时可靠的有效性及安全性也为此类抗体的标准化生产成药提供了很大的保障。.
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 12. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Chinesisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-04-12, Last update posted on www.tib.eu: 2024-04-24, Last updated: 2024-05-03 |
|---|
| Patentnummer: |
CN117866083 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA003763773 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA003763773 | ||
| 003 | DE-627 | ||
| 005 | 20240503105712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240426s2024 xx |||||o 00| ||chi c | ||
| 035 | |a (DE-627)EPA003763773 | ||
| 035 | |a (EPA)CN117866083 | ||
| 035 | |a (EPA)81030579 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 245 | 1 | 0 | |a 一种抗新型冠状病毒的全人源单克隆抗体及其用途 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-04-12, Last update posted on www.tib.eu: 2024-04-24, Last updated: 2024-05-03 | ||
| 520 | |a 本发明涉及一种抗新型冠状病毒的全人源单克隆抗体及其用途，属于生物工程技术领域。所述的全人源单克隆抗体具有重链可变区和轻链可变区；重链可变区的氨基酸序列如SEQ ID NO:15所示；轻链可变区的氨基酸序列如SEQ ID NO:16所示。本发明还提供该抗体的编码基因、表达载体、用途和组合物。本发明的结合分子能阻止新型冠状病毒侵染易感细胞，且是全人源的，与其它动物源性(如鼠源性)抗新型冠状病毒的分子相比，免疫原性低，且亲和性良好，不仅治疗效果好，而且副作用低，同时可靠的有效性及安全性也为此类抗体的标准化生产成药提供了很大的保障。 | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a tec | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 12. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:04 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/81030579/publication/CN117866083A1?q=CN117866083 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 04 | ||